KB-0742 Exhibits Tolerable Safety and Activity in Relapsed/R

The selective CDK9 inhibitor KB-0742 displayed anti-tumor activity and manageable safety as a single agent in heavily pretreated patients with relapsed/refractory, transcriptionally addicted solid tumors, according to data from a phase 1 trial (NCT04718675).

Related Keywords

California , United States , Miguel Villalona Calero , Therapeutics Research , Department Of Medical Oncology , International Conference On Molecular , Early Phase Therapeutics Program , Molecular Targets , Medical Oncology , Developmental Cancer Therapeutics Program , The Selective Cdk9 Inhibitor Kb 0742 , Heavily Pretreated Patients With Relapsed Refractory , Ranscriptionally Addicted Solid Tumors , Phase 1 Trial Nct04718675 , 2023 Aacr Nci Eortc International Conference On Molecular Targets And Cancer Therapeutics ,